

CITATION REPORT

List of articles citing

Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study

DOI: 10.7326/0003-4819-131-12-199912210-00004
Annals of Internal Medicine, 1999, 131, 927-34.

Source: <https://exaly.com/paper-pdf/31073706/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
457	Embolism and Stroke. 118-134		
456	Underuse of antithrombotic therapy in stroke patients with chronic atrial fibrillation. 2000 , 31, 2266-7		7
455	Kaiser Permanente's prescription drug benefit. 2000 , 19, 185-90		15
454	Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. 2000 , 102, 11-3		178
453	Oral anticoagulants. Pharmacologic issues for use in the elderly. 2001 , 17, 1-13		64
452	[Stroke management in a general internal medicine department: results of a survey regarding practice]. 2001 , 22, 830-44		2
451	Hemorrhagic complications of oral anticoagulant therapy. 2001 , 17, 49-56		23
450	To anticoagulate or not to anticoagulate patients with cardiomyopathy. 2001 , 19, 605-15		6
449	Atrial fibrillation and stroke : concepts and controversies. 2001 , 32, 803-8		260
448	Anticoagulation and heart failure. <i>Current Cardiology Reports</i> , 2001 , 3, 72-7	4.2	3
447	Targeting patients with atrial fibrillation and improving their anticoagulation management. 2001 , 24, 355-7		1
446	Is warfarin really underused in patients with atrial fibrillation?. 2001 , 16, 743-9		27
445	Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database. 2001 , 86, 284-8		189
444	Use of antihypertensive and antithrombotic medications after stroke in community-based care. 2001 , 35, 811-6		9
443	Effects of the September 11th attacks on urgent and emergent medical evaluations in a Northern California managed care plan. <i>American Journal of Medicine</i> , 2002 , 113, 556-62	2.4	11
442	Atrial fibrillation in the elderly: facts and management. 2002 , 19, 819-46		47
441	The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable. 2002 , 9, 268-72		23

440	Incidence of chronic atrial fibrillation in general practice and its treatment pattern. 2002 , 55, 358-63	158
439	Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. 2003 , 15, 41-6	21
438	Cardioembolic stroke: an update. 2003 , 2, 177-88	206
437	Physician compliance with outpatient oral anticoagulant guidelines in Auvergne, France. 2003 , 18, 903-7	8
436	Prevention of vascular events in patients with atrial fibrillation: evidence, guidelines, and practice. <i>Journal of Cardiovascular Electrophysiology</i> , 2003 , 14, S52-5	2.7 6
435	[Use of oral anticoagulants in patients discharged with atrial fibrillation in 2000]. 2003 , 56, 1057-63	4
434	[A prospective protocol increases oral anticoagulant prescription in patients with chronic, nonvalvular atrial fibrillation]. 2003 , 56, 971-7	3
433	Use of regression modeling to simulate patient-specific decision analysis for patients with nonvalvular atrial fibrillation. 2003 , 23, 361-8	4
432	Ximelagatran: a new antithrombotic option in atrial fibrillation. 2004 , 9, 151-62	2
431	Ximelagatran: an oral direct thrombin inhibitor. 2004 , 38, 1881-97	10
430	Ximelagatran: the first oral direct thrombin inhibitor. 2004 , 13, 403-13	20
429	Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. 2004 , 57, 798-806	74
428	The use of warfarin in veterans with atrial fibrillation. 2004 , 4, 18	12
427	The role of oral direct thrombin inhibitors in atrial fibrillation. 2004 , 24, 190S-198S	
426	Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). 2004 , 94, 947-51	57
425	Do population studies confirm the benefit of oral anticoagulation in atrial fibrillation demonstrated in clinical trials?. 2004 , 10 Suppl 1, 9-16	7
424	Why is warfarin underutilized in patients with atrial fibrillation?. 2004 , 10 Suppl 1, 21-5	6
423	Occurrence and quality of anticoagulant treatment of chronic atrial fibrillation in primary health care in Sweden: a retrospective study on electronic patient records. 2004 , 4, 1	16

422	The increasing need for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. 2004 , 79, 904-13	31
421	Warfarin and atrial fibrillation. 2004 , 13, 243-4	
420	Socioeconomic Implications of Long-Term Warfarin Use. 2004 , 12, 385-392	
419	Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor. 2004 , 2, 163-74	6
418	Trends in utilization of antithrombotic therapy in patients with atrial fibrillation before stroke onset in a community-based study, from 1985 through 1997. From scientific evidence to practice. 2004 , 38, 121-8	16
417	Non-valvular atrial fibrillation and stroke: implications for nursing practice and therapeutics. 2004 , 17, 65-73	3
416	Anticoagulation as thromboprophylaxis for atrial fibrillation: implications in the 'real world' and the need for risk stratification. 2005 , 16, 461-4	2
415	Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. 2005 , 127, 2049-56	181
414	A preliminary assessment of the critical differences between novel oral anticoagulants currently in development. 2005 , 45, 1004-17	14
413	Oral anticoagulation: challenges in the case-management setting. 2005 , 10, 39-50	7
412	Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. 2005 , 3, 1218-23	50
411	Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin. 2005 , 20, 1114-9	33
410	Effect of access to anticoagulation management services on warfarin use in patients with atrial fibrillation. 2005 , 25, 1062-7	15
409	[Atrial fibrillation and thromboprophylaxis in elderly patients]. 2005 , 94, 87-94	1
408	Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. 2005 , 26, 2422-34	613
407	Anticoagulation for atrial fibrillation in the elderly. 2005 , 14, 81-6	5
406	Emerging role of direct thrombin inhibitors in nonvalvular atrial fibrillation: potential and peril. 2005 , 10, 11-21	7
405	Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the ANticoagulation and Risk factors In Atrial fibrillation (ATRIA) study. 2005 , 112, 1687-91	357

404	Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. <i>Current Medical Research and Opinion</i> , 2005 , 21, 1583-94	2.5	51
403	Nonpharmacologic stroke prevention in atrial fibrillation. 2005 , 3, 619-33		41
402	Transcatheter occlusion of the left atrial appendage for stroke prevention. 2005 , 3, 1003-8		22
401	Strokes attributable to underuse of warfarin and antiplatelets. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2005 , 14, 55-7	2.8	5
400	Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. 2005 , 149, 650-6		162
399	Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. <i>American Journal of Medicine</i> , 2005 , 118, 612-7	2.4	244
398	Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study. 2005 , 39, 446-51		65
397	Atrial fibrillation: challenges and opportunities. 2006 , 22 Suppl C, 21C-26C		3
396	Antithrombotic therapy in atrial fibrillation. 2006 , 22, 155-66, x		6
395	[Oral anticoagulation for nonvalvular atrial fibrillation: are scientific recommendations effective and safe in daily clinical practice?]. 2006 , 59, 688-95		11
394	Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. <i>American Journal of Medicine</i> , 2006 , 119, 607-15	2.4	68
393	Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). 2006 , 151, 713-9		73 ²
392	A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: there remains an unmet need. 2006 , 151, 771-8		47
391	Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. 2006 , 151, 1187-93		83
390	Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. <i>Annals of Internal Medicine</i> , 2006 , 144, 475-84	8	145
389	Stroke management in women. 2006 , 2, 597-603		
388	Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice. 2006 , 60, 258-64		64
387	Thromboprophylaxis in atrial fibrillation: why, how, when and how can we do better?. 2006 , 60, 252-5		1

386	Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. 2006 , 54, 1231-6		177
385	Cardioembolic stroke. 2006 , 8, 310-6		56
384	Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. 2006 , 97, 538-43		88
383	Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. 2006 , 37, 1075-80		209
382	Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). 2006 , 27, 1954-64		139
381	Atrial fibrillation and stroke: from scientific evidence to practice. 2006 , 28, 251-7		3
380	Challenges of establishing new antithrombotic therapies in atrial fibrillation. 2007 , 116, 449-55		74
379	Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. 2007 , 38, 874-80		59
378	Use of long-term anticoagulation is associated with traumatic intracranial hemorrhage and subsequent mortality in elderly patients hospitalized after falls: analysis of the New York State Administrative Database. 2007 , 63, 519-24		49
377	Is quality of anticoagulation a 'wild card' in the treatment of patients with atrial fibrillation?. 2007 , 4, 72-3		1
376	Racial disparities in the filling of warfarin prescriptions for nonvalvular atrial fibrillation. 2007 , 333, 67-73		14
375	Death and disability from warfarin-associated intracranial and extracranial hemorrhages. <i>American Journal of Medicine</i> , 2007 , 120, 700-5	2.4	378
374	An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2007 , 23, 2071-81	2.5	7
373	Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. 2007 , 39, 371-91		68
372	Influence of age on the prescription of vitamin K antagonists in outpatients with permanent atrial fibrillation in France. 2007 , 16, 32-8		13
371	Antithrombotic drug prescription in atrial fibrillation and its rationale among general practitioners, internists and cardiologists in The Netherlands--The EXAMINE-AF study. A questionnaire survey. 2007 , 61, 24-31		29
370	Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study. 2007 , 7, 203		11
369	Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). 2007 , 100, 1419-26		339

368	Atrial fibrillation and stroke prevention. 2007 , 6, 981-93		174
367	Application of a decision support tool for anticoagulation in patients with non-valvular atrial fibrillation. 2008 , 23, 411-7		25
366	Stroke due to atrial fibrillation and the attitude to prescribing anticoagulant prevention in Italy. A prospective study of a consecutive stroke population admitted to a comprehensive stroke unit. 2008 , 255, 796-802		15
365	Examining warfarin underutilization rates in patients with atrial fibrillation: Detailed chart review essential to capture contraindications to warfarin therapy. 2008 , 6, 6		41
364	The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 2008 , 133, 299S-339S		621
363	Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. 2008 , 51, 810-5		257
362	Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005. 2008 , 155, 829-40		14
361	Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation--a nationwide descriptive study in Taiwan. 2008 , 30, 1726-36		119
360	Anticoagulation in atrial fibrillation: the trials and tribulations of keeping within therapeutic range. <i>Current Medical Research and Opinion</i> , 2008 , 24, 1455-8	2.5	10
359	Will warfarin soon be pass? New approaches to stroke prevention in atrial fibrillation. 2008 , 52, 18-27		9
358	Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 2008 , 133, 546S-592S		595
357	Response to Letter Regarding Article, "Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation" 2008 , 117,		
356	Performance of comorbidity measures to predict stroke and death in a community-dwelling, hypertensive Medicaid population. 2008 , 39, 1938-44		41
355	Pharmacotherapy of atrial fibrillation: an old option with new possibilities. 2008 , 9, 913-25		4
354	Current status of anticoagulation therapy for elderly atrial fibrillation patients in Japan: from Hokuriku atrial fibrillation trial. 2008 , 72, 2058-61		14
353	Pharmacological Management of Atrial Fibrillation. 2008 , 37-47		1
352	New therapies for stroke prevention in atrial fibrillation: the long road to enhanced efficacy. 2009 , 120, 1024-6		3
351	Left atrial appendage occlusion eliminates the need for warfarin. 2009 , 120, 1919-26; discussion 1926		37

350	Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. 2009 , 119, 1363-9		307
349	Antithrombotic strategies in patients on oral anticoagulant therapy undergoing percutaneous coronary intervention: a proposed algorithm based on individual risk stratification. 2010 , 75, 128-34		5
348	New pharmacotherapy for stroke prevention in atrial fibrillation: update 2010. 2009 , 26, 1058-71		8
347	Clinical consequences of hospital variation in use of oral anticoagulant therapy after first-time admission for atrial fibrillation. 2009 , 265, 335-44		3
346	New antithrombotic drugs. 2009 , 86, 139-46		77
345	Adverse drug reactions related to hospital admission in Slovak elderly patients. 2009 , 48, 186-90		24
344	Thromboembolic and haemorrhagic events in permanent atrial fibrillation: observational study in an emergency department. 2009 , 20, 756-9		1
343	Quality of care for atrial fibrillation among patients hospitalized for heart failure. 2009 , 54, 1280-9		108
342	Stroke prevention in atrial fibrillation: WATCHMAN versus warfarin. 2009 , 7, 727-9		11
341	Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. 2009 , 374, 534-42		1373
340	Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. 2009 , 84, 1079-94		95
339	Update on medical management of atrial fibrillation in the modern era. 2009 , 6, S17-22		7
338	The net clinical benefit of warfarin anticoagulation in atrial fibrillation. <i>Annals of Internal Medicine</i> , 2009 , 151, 297-305	8	471
337	Managing thromboembolic risk in patients with atrial fibrillation: are we approaching a new frontier?. 2010 , 7, 107-110		1
336	Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. 2010 , 25, 312-20		25
335	Percutaneous left atrial appendage occlusion in atrial fibrillation: Who, how and why?. 2010 , 5, 418-422		4
334	Left atrial appendage closure. <i>Current Cardiology Reports</i> , 2010 , 12, 413-21	4.2	23
333	Association of warfarin use with CHADS(2) score in 441 patients with nonvalvular atrial fibrillation and no contraindications to warfarin. 2010 , 13, 172-4		2

332	Medical treatment of patients with atrial fibrillation aged over 80 years in daily clinical practice: influence of age and CHADS(2) score. 2010 , 50, 36-41	7
331	Modern role for clopidogrel in management of atrial fibrillation and stroke reduction. 2010 , 6, 95-103	4
330	Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. 2010 , 4, 51-60	83
329	Stroke in atrial fibrillation--hope on the horizon?. 2010 , 7 Suppl 6, S765-9	8
328	Warfarin discontinuation after starting warfarin for atrial fibrillation. 2010 , 3, 624-31	149
327	Atrial fibrillation in heart failure is associated with an increased risk of death only in patients with ischaemic heart disease. 2010 , 12, 692-7	20
326	Racial disparities in awareness and treatment of atrial fibrillation: the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. 2010 , 41, 581-7	111
325	Principles of Anticoagulation and New Therapeutic Agents in Atrial Fibrillation. 2010 , 2, 479-492	0
324	Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban. 2010 , 50, 986-1000	4
323	Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. 2010 , 56, 827-37	168
322	Medication errors in acute cardiovascular and stroke patients: a scientific statement from the American Heart Association. 2010 , 121, 1664-82	60
321	Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. 2010 , 21, 516-23	44
320	Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. 2010 , 159, 348-353.e1	118
319	Underuse of oral anticoagulants in atrial fibrillation: a systematic review. <i>American Journal of Medicine</i> , 2010 , 123, 638-645.e4	2.4 677
318	Dabigatran etexilate: advances in anticoagulation therapy. 2010 , 8, 771-4	4
317	Could geriatric characteristics explain the under-prescription of anticoagulation therapy for older patients admitted with atrial fibrillation? A retrospective observational study. 2010 , 27, 807-13	36
316	Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. 2011 , 9, 279-86	14
315	Stroke prevention versus bleeding risk in atrial fibrillation: a clinical dilemma. 2011 , 57, 181-3	16

314	A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. 2011 , 58, 395-401		610
313	Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). 2011 , 58, 493-501		124
312	Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. 2011 , 365, 883-91		6302
311	Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. <i>BMJ, The</i> , 2011 , 342, d124	5.9	913
310	Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. 2011 , 106, 739-49		332
309	Feasibility of closed-chest ligation of the left atrial appendage in humans. 2011 , 8, 188-93		114
308	Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. 2011 , 162, 606-612.e1		120
307	Management of atrial fibrillation: translating clinical trial data into clinical practice. <i>American Journal of Medicine</i> , 2011 , 124, 4-14	2.4	12
306	Apixaban versus warfarin in patients with atrial fibrillation. 2011 , 365, 981-92		5856
305	Anticoagulation remains underused in prevention of stroke associated with atrial fibrillation: insights from two consecutive national surveys. 2011 , 152, 356-61		5
304	Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients. 2011 , 106, 34-44		31
303	Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation. 2011 , 26, 294-9		4
302	Current and emerging therapies for stroke prophylaxis in atrial fibrillation. 2011 , 1, 1019-1037		
301	Evaluation of antithrombotic usage for atrial fibrillation in aged care facilities. 2011 , 36, 166-71		14
300	Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. 2011 , 9, 1460-7		151
299	Are the risk factors listed in warfarin prescribing information associated with anticoagulation-related bleeding? A systematic literature review. 2011 , 65, 749-63		3
298	Characterization of the proportion of untreated and antiplatelet therapy treated patients with atrial fibrillation. 2011 , 108, 151-61		31
297	Dabigatran in atrial fibrillation: pharmacology and clinical trials. 2011 , 32, 173-80		6

296	Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. 2011 , 77, 700-6		305
295	Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence. 2011 , 39, 7-16		1
294	Update on anti-coagulation in atrial fibrillation. 2011 , 104, 747-60		5
293	Quality of management of oral anticoagulation as assessed by time in therapeutic INR range in elderly and younger patients with low mean years of formal education: a prospective cohort study. 2011 , 40, 375-81		15
292	Newer anticoagulants for non-valvular atrial fibrillation. 2012 , 5, 469-80		3
291	Left atrial appendage exclusion for stroke prevention in atrial fibrillation. 2012 , 2012, 610827		13
290	Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. 2012 , 125, 159-64; discussion 164		68
289	Why is warfarin underused for stroke prevention in atrial fibrillation? A detailed review of electronic medical records. <i>Current Medical Research and Opinion</i> , 2012 , 28, 1407-14	2.5	21
288	Oral factor Xa and direct thrombin inhibitors: a clinical perspective. 2012 , 33, 453-61		1
287	Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation. 2012 , 11, 45-54		1
286	Does catheter ablation for atrial fibrillation increase or reduce neurological insult?. 2012 , 27, 36-40		2
285	Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation. 2012 , 27, 331-9		9
284	Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. 2012 , 43, 1795-9		61
283	Novel drugs for oral anticoagulation pharmacotherapy. 2012 , 10, 473-88		6
282	Preventing stroke in atrial fibrillation patients - clinical utility of oral anticoagulants. 2012 , 3, 1-13		
281	The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. 2012 , 81, 469-76		67
280	Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 2012 , 141, e326S-e350S		1175
279	Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation. 2012 , 33, 1886-92		56

278	Evidence-based percutaneous closure of the left atrial appendage in patients with atrial fibrillation. 2012 , 8, 37-42		8
277	Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. 2012 , 10, 1745-51		85
276	Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. 2012 , 380, 1749-58		150
275	Diagnosis and management of atrial fibrillation by primary care physicians in Italy : a retrospective, observational analysis. 2012 , 32, 771-7		6
274	Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. 2012 , 9, 1403-8		24
273	[Prevention of thromboembolism in atrial fibrillation]. 2012 , 31 Suppl 1, 17-26		1
272	[Dabigatran: transforming the management of oral anticoagulation]. 2012 , 212 Suppl 2, 15-22		
271	[Anticoagulation and atrial fibrillation]. 2012 , 43, 308-12		
270	National trends in oral anticoagulant use in the United States, 2007 to 2011. 2012 , 5, 615-21		249
269	Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation. <i>Thrombosis Research</i> , 2012 , 129, 9-16	8.2	7
268	Oral direct factor Xa inhibitors. 2012 , 111, 1069-78		78
267	The physics of geriatric pharmacotherapy: overcoming therapeutic inertia and momentum. <i>American Journal of Medicine</i> , 2012 , 125, 523-4	2.4	9
266	Warfarin use in nursing home residents: results from the 2004 national nursing home survey. 2012 , 10, 25-36.e2		18
265	Novel anticoagulants for non-valvular atrial fibrillation. 2012 , 21, 463-7		6
264	Stroke prevention in atrial fibrillation: latest clinical trials and guidelines. 2012 , 5, 384-97		2
263	Randomized trial of lottery-based incentives to improve warfarin adherence. 2012 , 164, 268-74		83
262	The ATRIA risk scheme to predict warfarin-associated hemorrhage not ready for clinical use. 2012 , 59, 194-5; author reply 195		14
261	Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. <i>American Journal of Medicine</i> , 2012 , 125, 826.e13-23	2.4	62

260	Caregiver assistance among Medicare beneficiaries with atrial fibrillation and factors associated with anticoagulant treatment. 2012 , 10, 273-83		4
259	Left atrial appendage occlusion for stroke prevention. 2012 , 37, 405-41		16
258	Bridging with the Low molecular weight heparin certoparin in patients requiring temporary discontinuation of oral anticoagulation - the non-interventional, retrospective REMEMBER study. <i>Thrombosis Research</i> , 2012 , 130, 788-92	8.2	6
257	¿A qu`pacientes beneficia el uso de dabigatr`n? Uso pr`ctico. 2012 , 12, 37-43		
256	The effect of cognitive impairment in the elderly on the initial and long-term stability of warfarin therapy. 2012 , 29, 307-17		9
255	Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. 2012 , 7, e47473		55
254	[Apixaban]. 2012 , 32, 203-11		1
253	Early experience using a left atrial appendage occlusion device in patients with atrial fibrillation. 2012 , 53, 83-90		7
252	A systematic review of validated methods for identifying atrial fibrillation using administrative data. 2012 , 21 Suppl 1, 141-7		234
251	Dabigatran etexilate: what do hospitalists need to know?. 2012 , 7, 262-9		4
250	The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. 2012 , 107, 1172-9		326
249	Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation. 2012 , 271, 15-24		39
248	Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. 2012 , 11, 503-11		212
247	Novel antithrombotic agents for atrial fibrillation. 2012 , 134, 345-54		3
246	Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis. 2012 , 13, 5		70
245	Promise of factor Xa inhibition in atrial fibrillation. <i>Current Cardiology Reports</i> , 2012 , 14, 70-8	4.2	2
244	Differences and time trends in drug treatment of atrial fibrillation in men and women and doctors' adherence to warfarin therapy recommendations: a Swedish study of prescribed drugs in primary care in 2002 and 2007. 2013 , 69, 245-53		25
243	New oral anticoagulants in elderly patients. 2013 , 26, 215-24		53

242	Retinal vein and artery occlusions: a risk factor for stroke in atrial fibrillation. 2013 , 11, 1485-92		30
241	Oral anticoagulants in older adults with atrial fibrillation. 2013 , 36, 403-15		3
240	Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation. <i>American Journal of Medicine</i> , 2013 , 126, 625-32.e1	2.4	31
239	Contemporary Management of Atrial Fibrillation. 2013 , 9, 643-652		4
238	Women hospitalized with atrial fibrillation: gender differences, trends and outcome from a 20-year registry in a Middle Eastern country (1991-2010). 2013 , 168, 975-80		16
237	Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. 2013 , 62, 108-118		314
236	La fibrillation atriale chez la personne âgée: déterminants de la prescription d'anticoagulants. Étude originale réalisée chez 170 résidents de l'HPAD. 2013 , 5, 268-273		
235	Factors associated with undertreatment of atrial fibrillation in geriatric outpatients with Alzheimer disease. 2013 , 13, 425-33		18
234	Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. 2013 , 36, 163-74		15
233	Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. 2013 , 11, 1029-49		4
232	Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. 2013 , 127, 930-7		171
231	Atrial fibrillation and risk of stroke in dialysis patients. 2013 , 23, 112-8		47
230	Current presentation and management of 7148 patients with atrial fibrillation in cardiology and internal medicine hospital centers: the ATA AF study. 2013 , 167, 2895-903		54
229	Fibrillation atriale non valvulaire : traitement antithrombotique conventionnel (antivitamines K et antiagrégants plaquettaires). 2013 , 5, 132-140		
228	The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. 2013 , 29, 190-200		60
227	Managing anticoagulation for atrial fibrillation: current issues and future strategies. 2013 , 273, 31-41		7
226	Thromboprophylaxis in the oldest old with atrial fibrillation: between Scylla and Charybdis. 2013 , 24, 285-7		10
225	New oral anticoagulants in elderly patients with atrial fibrillation. <i>American Journal of Medicine</i> , 2013 , 126, 289-96	2.4	29

224	Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care. 2013 , 67, 647-55		3
223	Gender differences of bleeding and stroke risk in very old atrial fibrillation patients on VKA treatment: results of the EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics). <i>Thrombosis Research</i> , 2013 , 131, 12-6	8.2	32
222	Factors that influence awareness and treatment of atrial fibrillation in older adults. 2013 , 106, 415-24		35
221	Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. 2013 , 6, 461-9		61
220	Comparison of Atrial Fibrillation in the Young versus That in the Elderly: A Review. 2013 , 2013, 976976		36
219	Left ventricular assist device-induced coagulation and platelet activation and effect of the current anticoagulant therapy regimen. 2013 , 19, 249-55		11
218	A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. <i>Journal of the American Heart Association</i> , 2013 , 2, e000250	6	225
217	National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries. 2013 , 47, 35-42		31
216	Secular trends, treatments, and outcomes of Middle Eastern Arab and South Asian patients hospitalized with atrial fibrillation: insights from a 20-year registry in Qatar (1991-2010). 2013 , 64, 498-504		8
215	Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation. 2013 , 11, 1619-29		12
214	Dabigatran-induced hyperkalemia in a renal transplant recipient: a clinical observation. 2013 , 53, 456-8		4
213	Guideline adherence of antithrombotic treatment initiated by general practitioners in patients with nonvalvular atrial fibrillation: a Danish survey. 2013 , 36, 427-32		22
212	Real-world management of atrial fibrillation in Internal Medicine units: the FADOI 'FALP' observational study. 2013 , 14, 26-34		7
211	Analysis of antithrombotic therapy after cardioembolic stroke due to atrial fibrillation or flutter. 2013 , 48, 127-33		
210	Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. 2014 , 85, 1412-20		55
209	Long-term survival after ischemic stroke in patients with atrial fibrillation. 2014 , 82, 1033-7		30
208	Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive and validate the Qbleed scores. <i>BMJ, The</i> , 2014 , 349, g4606	5.9	54
207	Prevention of Stroke in Patients With Atrial Fibrillation. 2014 , 1129-1137		

206	Thrombo-prevention in membranous nephropathy: a new tool for decision making?. 2014 , 85, 1265-6		2
205	The atrial fibrillation epidemic: a validated diagnosis, or not?. 2014 , 16, 1701-2		2
204	Oral anticoagulant therapy and clinical outcomes in patients with atrial fibrillation: a pilot study from a single center registry. 2014 , 25, 688-94		
203	Physician's fear of anticoagulant therapy in nonvalvular atrial fibrillation. 2014 , 348, 513-21		36
202	The efficacy of rivaroxaban in patients with atrial fibrillation. 2014 , 21, 412-8		2
201	Atrial fibrillation in the elderly: management strategies to achieve performance measures. <i>AACN Advanced Critical Care</i> , 2014 , 25, 205-12	1	3
200	Antiarrhythmic strategies in patients with atrial fibrillation managed by cardiologists and internists: Antithrombotic Agents in Atrial Fibrillation (ATA-AF) survey. 2014 , 15, 626-35		2
199	Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making. 2014 , 5, 21-37		11
198	Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. 2014 , 35, 1856-63		20
197	Patient-centered medical homes and oral anticoagulation therapy initiation. 2014 , 71, 174-91		4
196	Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. 2014 , 167, 601-609.e1		103
195	Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm. 2014 , 174, 471-83		14
194	Neurointerventional Therapies for Stroke in Atrial Fibrillation: Illustrated Cases. 2014 , 6, 169-80		
193	The nephrologist's anticoagulation treatment patterns/regimens in chronic hemodialysis patients with atrial fibrillation. 2014 , 27, 187-92		12
192	Warfarin and atrial fibrillation: from ideal to real the warfarin affaire. 2014 , 12, 5		26
191	Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey. 2014 , 107, 77-87		68
190	Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. 2014 , 7, 113-24		54
189	Comparing the imperfect with the imperfect: the imprecise science of assessing the risk and benefits of anticoagulation in atrial fibrillation. 2014 , 129, 1997-9		4

188	Left atrial appendage occlusion: opportunities and challenges. 2014 , 63, 291-8		53
187	Cardiac procedures to prevent stroke: patent foramen ovale closure/left atrial appendage occlusion. 2014 , 30, 87-95		9
186	Novel oral anticoagulants for stroke prevention in the geriatric population. 2014 , 14, 15-29		3
185	Associations with anticoagulation: a cross-sectional registry-based analysis of stroke survivors with atrial fibrillation. 2014 , 100, 557-62		17
184	The economic burden to medicare of stroke events in atrial fibrillation populations with and without thromboprophylaxis. 2014 , 17, 159-65		7
183	Renal function, attributes and coagulation treatment in atrial fibrillation (R-FACT Study): retrospective, observational, longitudinal cohort study of renal function and antithrombotic treatment patterns in atrial fibrillation patients with documented eGFR in real-world clinical practice in Germany. 2014 , 18, 711-21		2
182	Left atrial appendage exclusion for prevention of stroke in atrial fibrillation: review of minimally invasive approaches. <i>Current Cardiology Reports</i> , 2014 , 16, 448	4.2	8
181	Adherence to guidelines and mortality in atrial fibrillation. 2014 , 176, 430-6		13
180	Drug Therapies for Stroke Prevention in Atrial Fibrillation: An Historical Perspective. 2014 , 6, 61-78		
179	Ensuring medication adherence with direct oral anticoagulant drugs: lessons from adherence with vitamin K antagonists (VKAs). <i>Thrombosis Research</i> , 2014 , 133, 699-704	8.2	37
178	Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. 2014 , 114, 583-6		53
177	A non-experimental study of oral anticoagulation therapy initiation before and after national patient safety goals. 2014 , 4, e003960		1
176	The value of the European society of cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score: a nationwide cohort study. 2014 , 146, 1337-1346		29
175	A review of the LARIAT device: insights from the cumulative clinical experience. 2015 , 4, 522		16
174	Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation. 2015 , 33, 177-83		48
173	A common data model to assess cardiovascular hospitalization and mortality in atrial fibrillation patients using administrative claims and medical records. 2015 , 7, 77-90		10
172	Blending Quality Improvement and Research Methods for Implementation Science, Part II: Analysis of the Quality of Implementation. <i>AACN Advanced Critical Care</i> , 2015 , 26, 366-71	1	2
171	The risks of risk scores for stroke risk assessment in atrial fibrillation. 2015 , 113, 1170-3		39

170	Variation in Anticoagulant Recommendations by the Guidelines and Decision Tools among Patients with Atrial Fibrillation. 2015 , 3, 130-45	8
169	Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc ≥ 1 , or higher?. 2015 , 113, 1165-9	40
168	How does Chronic Atrial Fibrillation Influence Mortality in the Modern Treatment Era?. 2015 , 11, 190-8	22
167	An automated clinical alert system for newly-diagnosed atrial fibrillation. 2015 , 10, e0122153	17
166	Variability of the Left Atrial Appendage in Human Hearts. 2015 , 10, e0141901	18
165	Atrial Fibrillation: Pathophysiology and Therapeutic Options. 2015 , 29, 1333-40	17
164	Cardiac CT angiography for device surveillance after endovascular left atrial appendage closure. 2015 , 16, 1198-206	85
163	Strategies to incorporate left atrial appendage occlusion into clinical practice. 2015 , 65, 2337-44	7
162	Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. 2015 , 147, 109-119	161
161	Percutaneous left atrial appendage closure: a review of the WATCHMAN clinical trial experience. 2015 , 7, 333-344	
160	Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. 2015 , 36, 297-306	108
159	Differences in anticoagulant therapy prescription in patients with paroxysmal versus persistent atrial fibrillation. <i>American Journal of Medicine</i> , 2015 , 128, 654.e1-654.e10	2.4 32
158	Correlates and outcomes of warfarin initiation in kidney transplant recipients newly diagnosed with atrial fibrillation. 2015 , 30, 321-9	13
157	Relationship between stroke and mortality in dialysis patients. 2015 , 10, 80-9	23
156	Left atrial appendage occlusion debate revisited. 2015 , 131, 756-61	17
155	Safety and effectiveness of compassionate use of LARIAT [®] device for epicardial ligation of anatomically complex left atrial appendages. 2015 , 42, 11-9	5
154	Left atrial appendage occlusion for stroke prevention. 2015 , 40, 429-76	6
153	Underutilization of warfarin for stroke prophylaxis in patients with atrial fibrillation or atrial flutter in Korea. 2015 , 66, 475-81	17

152	Metabolic syndrome, atrial fibrillation, and stroke: Tackling an emerging epidemic. 2015 , 12, 2332-43	21
151	Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk. 2015 , 58, 177-94	26
150	Evaluation of oral anticoagulation therapy: rationale and design of the thrombEVAL study programme. 2015 , 22, 622-8	15
149	Neighborhood deprivation and warfarin, aspirin and statin prescription - A cohort study of men and women treated for atrial fibrillation in Swedish primary care. 2015 , 187, 547-52	18
148	Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service--results from the prospective, multi-center, observational cohort study thrombEVAL. 2015 , 13, 14	31
147	Oral Anticoagulant Prescription in Patients With Atrial Fibrillation and a Low Risk of Thromboembolism: Insights From the NCDR PINNACLE Registry. 2015 , 175, 1062-5	17
146	Percutaneous left atrial appendage closure: Technical aspects and prevention of periprocedural complications with the watchman device. 2015 , 7, 65-75	28
145	Coronary heart disease risk factors and outcomes in the twenty-first century: findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. 2015 , 17, 541	15
144	The effect of dabigatran and rivaroxaban on platelet reactivity and inflammatory markers. 2015 , 40, 340-6	23
143	Will NOACs become the new standard of care in anticoagulation therapy?. 2015 , 1, 1-4	12
142	Stroke with atrial fibrillation or atrial flutter: a descriptive population-based study from the Brest stroke registry. 2015 , 15, 63	7
141	The safety and efficacy of vitamin K antagonist in patients with atrial fibrillation and liver cirrhosis. 2015 , 180, 185-91	28
140	Early results with the LARIAT device for left atrial appendage exclusion in patients with atrial fibrillation at high risk for stroke and anticoagulation. 2015 , 86, 121-7	48
139	Management of Atrial Fibrillation. 2015 , 30, 484-98	5
138	Use of Vitamins K antagonists in non-valvular atrial fibrillation thromboembolic risk prevention in Burkina Faso. 2016 , 24, 108	7
137	Percutaneous left atrial appendage closure devices: safety, efficacy, and clinical utility. 2016 , 9, 309-16	1
136	Left atrial appendage exclusion for atrial fibrillation: does the protection from stroke prevail in the long-term?. 2016 , 8, E1260-E1267	2
135	Using an Atrial Fibrillation Decision Support Tool for Thromboprophylaxis in Atrial Fibrillation: Effect of Sex and Age. 2016 , 64, 1054-60	13

134	Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	12
133	Suboptimal use of non-vitamin K antagonist oral anticoagulants: Results from the RAMSES study. 2016 , 95, e4672		22
132	Antithrombotic therapy in patients with non-valvular atrial fibrillation in Southern Sweden: A population-based cohort study. <i>Thrombosis Research</i> , 2016 , 140, 94-99	8.2	19
131	Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation. 2016 , 18, 65		6
130	Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial. 2016 , 39, 497-506		4
129	A prospective study investigating the causes of warfarin under-utilization in Chinese patients. 2016 , 38, 1286-93		4
128	A randomized trial of lottery-based incentives and reminders to improve warfarin adherence: the Warfarin Incentives (WIN2) Trial. 2016 , 25, 1219-1227		17
127	Blending Quality Improvement and Research Methods for Implementation Science, Part III: Analysis of the Effectiveness of Implementation. <i>AACN Advanced Critical Care</i> , 2016 , 27, 103-10	1	2
126	Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. 2016 , 6, 27410		48
125	Adoption of direct oral anticoagulants for stroke prevention in atrial fibrillation. 2016 , 46, 792-7		16
124	Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke. 2016 , 67, 2913-23		95
123	How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation?. 2016 , 118, 697-9		9
122	Impact of an Atrial Fibrillation Decision Support Tool on thromboprophylaxis for atrial fibrillation. 2016 , 176, 17-27		29
121	Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants. 2016 , 30, 201-14		15
120	Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients: ATRIA Study. 2016 , 67, 239-47		53
119	Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. 2016 , 18, 979-86		33
118	Medical Practice Variations in Stroke. 2016 , 259-296		
117	Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study. 2016 , 176, 10-6		5

116	A Simple and Portable Algorithm for Identifying Atrial Fibrillation in the Electronic Medical Record. 2016 , 117, 221-5		27
115	Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. 2016 , 45, 77-83		72
114	The Effect of Bleeding Risk and Frailty Status on Anticoagulation Patterns in Octogenarians With Atrial Fibrillation: The FRAIL-AF Study. 2016 , 32, 169-76		86
113	Cardiac CT Angiography (CCTA) predicts left atrial appendage occluder device size and procedure outcome. 2017 , 33, 739-747		15
112	Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF. 2017 , 232, 98-104		13
111	Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation. 2017 , 34, 1283-1290		4
110	Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation. 2017 , 69, 2475-2484		158
109	Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients. 2017 , 12, 425-435		6
108	Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. <i>Current Medical Research and Opinion</i> , 2017 , 33, 1745-1754	2.5	52
107	Clinical Features and Prognosis in Patients with Atrial Fibrillation and Prior Stroke: Comparing the Fushimi and Darlington AF Registries. 2017 , 18, 199-203		11
106	Direct acting oral anticoagulant: Bench to bedside. 2017 , 73, 274-281		
105	Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk. <i>Current Medical Research and Opinion</i> , 2017 , 33, 631-638	2.5	
104	Use of Oral Anticoagulant Therapy in Older Adults with Atrial Fibrillation After Acute Ischemic Stroke. 2017 , 65, 241-248		40
103	Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients. 2017 , 33, 475-482		15
102	Safety and efficacy of rivaroxaban compared with warfarin in patients undergoing peripheral arterial procedures. 2017 , 66, 1143-1148		6
101	Interventional and surgical occlusion of the left atrial appendage. 2017 , 14, 727-743		24
100	Recent Advances in Stroke Prevention in Patients with Atrial Fibrillation and End-Stage Renal Disease. 2017 , 7, 207-217		12
99	Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice. 2017 , 11, 105-120		5

98	Left atrial appendage closure: A single center experience and comparison of two contemporary devices. 2017 , 89, 763-772		20
97	Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study. 2017 , 65, 35-41		9
96	ANMCO/AIAC/SICI-GISE/SIC/SICCH Consensus Document: percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation patients: indications, patient selection, staff skills, organisation, and training. 2017 , 19, D333-D353		21
95	Sex-Related Differences in the Clinical Events of Patients With Atrial Fibrillation - The Fushimi AF Registry. 2017 , 81, 1403-1410		12
94	Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation. 2017 , 23, 1191-1201		16
93	Diabetes mellitus and stroke: A clinical update. 2017 , 8, 235-248		64
92	The Trends of Atrial Fibrillation-Related Hospital Visit and Cost, Treatment Pattern and Mortality in Korea: 10-Year Nationwide Sample Cohort Data. 2017 , 47, 56-64		59
91	Using the Symmetry Analysis Design to Screen for Adverse Effects of Non-vitamin K Antagonist Oral Anticoagulants. 2018 , 41, 685-695		6
90	Anxiety, Depression, and Adverse Clinical Outcomes in Patients With Atrial Fibrillation Starting Warfarin: Cardiovascular Research Network WAVE Study. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	20
89	Contemporary approach to stroke prevention in atrial fibrillation: Risks, benefits, and new options. 2018 , 28, 469-480		0
88	Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review. 2018 , 104, 301-310		11
87	Pre-admission proteinuria impacts risk of non-recovery after dialysis-requiring acute kidney injury. 2018 , 93, 968-976		11
86	Percutaneous left atrial appendage occlusion in atrial fibrillation patients with a contraindication to oral anticoagulation: a focused review. 2018 , 20, 1412-1419		11
85	Predictors of oral anticoagulant non-prescription in patients with atrial fibrillation and elevated stroke risk. 2018 , 200, 24-31		22
84	Transcatheter closure of the left atrial appendage: A focused update on the Watchman closure device. 2018 , 92, E28-E34		1
83	Selecting antithrombotic therapy for stroke prevention in atrial fibrillation: Health professionals' feedback on a decision support tool. 2018 , 24, 309-322		5
82	Prevention of Stroke in Atrial Fibrillation. 2018 , 1092-1100		
81	Accuracy of Commonly-Used Imaging Modalities in Assessing Left Atrial Appendage for Interventional Closure: Review Article. 2018 , 7,		4

80	Effect of Variation in Published Stroke Rates on the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2018 , 169, 517-527	8	13
79	Association of Burden of Atrial Fibrillation With Risk of Ischemic Stroke in Adults With Paroxysmal Atrial Fibrillation: The KP-RHYTHM Study. 2018 , 3, 601-608		124
78	Prestroke and Poststroke Antithrombotic Therapy in Patients With Atrial Fibrillation: Results From a Nationwide Cohort. 2018 , 1, e180171		18
77	Electronic physician notifications to improve guideline-based anticoagulation in atrial fibrillation: a randomized controlled trial. 2018 , 33, 2070-2077		15
76	A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents. 2018 , 7,		24
75	Anticoagulation therapy in patients with stroke and atrial fibrillation: a registry-based study of acute stroke care in Surrey, UK. 2018 , 8, e022558		13
74	Safety of Direct Oral Anticoagulants and Vitamin K Antagonists in Oldest Old Patients: A Prospective Study. 2018 , 19, 936-941		9
73	Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke: Findings From the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. 2019 , 76, 1192-1202		49
72	Ischemic and Bleeding Outcomes in Patients With Atrial Fibrillation and Contraindications to Oral Anticoagulation. 2019 , 5, 1384-1392		5
71	Kidney function, proteinuria and breast arterial calcification in women without clinical cardiovascular disease: The MINERVA study. 2019 , 14, e0210973		4
70	Left Atrial Appendage Occlusion: A Narrative Review. 2019 , 33, 1753-1765		8
69	Efficacy and safety of rivaroxaban on the resolution of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation patients. 2019 , 48, 270-276		13
68	Disparities and Temporal Trends in the Use of Anticoagulation in Patients With Ischemic Stroke and Atrial Fibrillation. 2019 , 50, 1452-1459		21
67	Predicting Renal Recovery After Dialysis-Requiring Acute Kidney Injury. 2019 , 4, 571-581		24
66	Acute Coronary Syndrome in Idiopathic Inflammatory Myopathies: A Population-based Study. 2019 , 46, 1509-1514		7
65	Risk factors for medication non-adherence among atrial fibrillation patients. 2019 , 19, 38		18
64	Exploring patient-provider decision-making for use of anticoagulation for stroke prevention in atrial fibrillation: Results of the INFORM-AF study. 2019 , 18, 280-288		8
63	Stroke prevention in atrial fibrillation: Closing the gap. 2019 , 210, 29-38		6

62	Thoracoscopic Left Atrial Appendage Occlusion for Stroke Prevention Compared with Long-Term Warfarin Therapy in Patients With Nonvalvular Atrial Fibrillation. 2019 , 123, 50-56		3
61	Shake Rattle & Roll - Design and rationale for a pragmatic trial to improve blood pressure control among blacks with persistent hypertension. 2019 , 76, 85-92		7
60	Risk Stratification in Atrial Fibrillation. 2019 , 47-66		
59	New oral anticoagulants for nonvalvular atrial fibrillation with stable coronary artery disease: A meta-analysis. 2020 , 43, 1393-1400		1
58	New oral anticoagulants for nonvalvular atrial fibrillation with peripheral artery disease: a meta-analysis. 2021 , 46, 352-358		
57	Impact of Different Electronic Cohort Definitions to Identify Patients With Atrial Fibrillation From the Electronic Medical Record. <i>Journal of the American Heart Association</i> , 2020 , 9, e014527	6	8
56	Outcome of non-vitamin K oral anticoagulants in the treatment of left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2020 , 31, 658-663	2.7	4
55	Comparative Analysis of Risk Stratification Scores in Atrial Fibrillation. <i>Current Pharmaceutical Design</i> , 2021 , 27, 1298-1310	3.3	1
54	The Proportion of Preventable Thrombectomy Procedures with Improved Atrial Fibrillation Stroke Prevention. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021 , 30, 105599	2.8	0
53	Effects of Colchicine on Cardiovascular Outcomes in Patients with Coronary Artery Disease: A Systematic Review and One-Stage and Two-Stage Meta-Analysis of Randomized-Controlled Trials. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021 , 28, 343-354	2.9	2
52	Preclinical Assessment of a Novel Conformable Foam-Based Left Atrial Appendage Closure Device. <i>BioMed Research International</i> , 2021 , 2021, 4556400	3	1
51	Oral Anticoagulation Use in High-Risk Patients Is Improved by Elimination of False-Positive and Inactive Atrial Fibrillation Cases. <i>American Journal of Medicine</i> , 2021 , 134, e366-e373	2.4	0
50	Perioperative Resumption of Direct Oral Anticoagulants: Review of the Mayo Clinic Experience. <i>Southern Medical Journal</i> , 2021 , 114, 442-444	0.6	
49	Cardiovascular care of older adults. <i>BMJ, The</i> , 2021 , 374, n1593	5.9	4
48	Cardiac Diseases. 2022 , 477-487.e6		
47	Stroke in atrial fibrillation: a need for effective anticoagulation. <i>Southern Medical Journal</i> , 2004 , 97, 919-205		1
46	Efficacy and safety of novel anticoagulants in the elderly. <i>Journal of Geriatric Cardiology</i> , 2016 , 13, 718-723		19
45	Novel oral anticoagulants for stroke prevention in atrial fibrillation: a focus on the older patient. <i>International Journal of General Medicine</i> , 2013 , 6, 167-80	2.3	13

44	Newer Oral Anticoagulants: Stroke Prevention and Pitfalls. <i>Open Cardiovascular Medicine Journal</i> , 2016 , 10, 94-104	0.7	6
43	Stroke prevention in patients with atrial fibrillation and comorbidities. <i>Systemic Hypertension</i> , 2018 , 15, 55-59	1.6	1
42	Prevalence of polymorphisms of CYP2C9 and VKORC1 in the Czech Republic and reflection on the views of anticoagulation therapy with warfarin. <i>Cor Et Vasa</i> , 2011 , 53, 522-526	0.3	2
41	Japanese Patients' and Physicians' Preferences for Anticoagulant Use in Atrial Fibrillation: Results from a Discrete-choice Experiment. <i>Journal of Health Economics and Outcomes Research</i> , 2014 , 2, 207-220	1.6	1
40	2018 KHRS Expert Consensus Recommendation for Oral Anticoagulants Choice and Appropriate Doses: Specific Situation and High Risk Patients. <i>Korean Journal of Medicine</i> , 2018 , 93, 110-132	0.5	6
39	Blending Quality Improvement and Research Methods for Implementation Science, Part II: Analysis of the Quality of Implementation. <i>AACN Advanced Critical Care</i> , 2015 , 26, 366-371	1	1
38	Assessing the quality, suitability and readability of internet-based health information about warfarin for patients. <i>Australasian Medical Journal</i> , 2012 , 5, 194-203	2	7
37	Impact of relative contraindications on the use, benefits, and risks of anticoagulant prophylaxis in atrial fibrillation: analysis of a claims database. <i>Open Journal of Internal Medicine</i> , 2011 , 01, 60-67	0.2	3
36	Comparison of cardiac computed tomography angiography and transoesophageal echocardiography for device surveillance after left atrial appendage closure. <i>EuroIntervention</i> , 2019 , 15, 663-670	3.1	29
35	Recent progress in antithrombotic therapy for atrial fibrillation. <i>Journal of Atherosclerosis and Thrombosis</i> , 2011 , 18, 257-73	4	3
34	Statement on Antiplatelet Agents and Anticoagulants in Cardiology - 2019. <i>Arquivos Brasileiros De Cardiologia</i> , 2019 , 113, 111-134	1.2	2
33	????????rhythm, rate control????? : ?????????Shinken Database 2004??(1.????????????,??1????????????). <i>Journal of JCS Cardiologists</i> , 2007 , 15, 199-206	0.1	
32	A review from clinical viewpoint. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2011 , 22, 156-163	0	
31	Anticoagulation for atrial fibrillation. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2012 , 23, 8-15	0	
30	Left Atrial Appendage Closure and Stroke. 2012 , 623-634		
29	????????????????(2.????????????????,??5????????????). <i>Journal of JCS Cardiologists</i> , 2012 , 20, 49-57	0.1	
28	Medical Practice Variations in Stroke. 2014 , 1-40		
27	Left Atrial Occluders/Isolation. 2014 , 1325-1332		

26	Atrial Fibrillation in the Elderly: Management Strategies to Achieve Performance Measures. <i>AACN Advanced Critical Care</i> , 2014 , 25, 205-212	1	1
25	Amplatzer Cardiac Plug and Amulet. <i>Contemporary Cardiology</i> , 2016 , 181-193	0.1	
24	Left Atrial Appendage Closure with Amplatzer Cardiac Plug in Nonvalvular Atrial Fibrillation: Safety and Long-Term Outcome. <i>Arquivos Brasileiros De Cardiologia</i> , 2017 , 109, 541-549	1.2	3
23	Recent Advances for Stroke Prevention in Patients With Atrial Fibrillation and Advanced Kidney Disease. 2019 , 736-740.e2		
22	Impact of geriatric syndromes on anticoagulation prescription in older adults with atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2021 , 1-5	2.5	0
21	Conformal Left Atrial Appendage Seal Device for Left Atrial Appendage Closure: First Clinical Use. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 2368-2374	5	0
20	Analysis of the Impact Factors on a Stable Warfarin Dose in Extreme Elderly (Age ≥80 Years) Chinese Patients with Non-Valvular Atrial Fibrillation. <i>World Journal of Cardiovascular Diseases</i> , 2020 , 10, 329-336	0	
19	Anticoagulation therapy for patients with atrial fibrillation. <i>Cmaj</i> , 2000 , 163, 956-7	3.5	2
18	Comorbidity associated with atrial fibrillation: a general practice-based study. <i>British Journal of General Practice</i> , 2001 , 51, 884-6, 889-91	1.6	23
17	Stroke prevention: age alone does not rule out warfarin. <i>Journal of Family Practice</i> , 2007 , 56, 902-6	0.2	1
16	Reviewing the medical literature: five notable articles in general internal medicine from 2010 and 2011. <i>Open Medicine</i> , 2012 , 6, e17-23		
15	Exclusion of the left atrial appendage to prevent stroke in cases of atrial fibrillation. <i>Texas Heart Institute Journal</i> , 2012 , 39, 535-7	0.8	2
14	Choices in the use of ICD-9 codes to identify stroke risk factors can affect the apparent population-level risk factor prevalence and distribution of CHADS2 scores. <i>American Journal of Cardiovascular Disease</i> , 2012 , 2, 184-91	0.9	26
13	Evaluation of an initiation protocol of 4 mg of warfarin for atrial fibrillation in the outpatient setting. <i>Canadian Family Physician</i> , 2014 , 60, e535-40	0.9	2
12	A Review of the LARIAT Suture Delivery Device for Left Atrial Appendage Closure. <i>The Journal of Tehran Heart Center</i> , 2015 , 10, 69-73	0.3	2
11	A Review Of Clinical Trials On LARIAT Device. <i>Journal of Atrial Fibrillation</i> , 2015 , 8, 1317	0.8	1
10	Complications From Left Atrial Appendage Exclusion Devices. <i>Journal of Atrial Fibrillation</i> , 2014 , 7, 1034	0.8	10
9	Non-Vitamin K Oral Anticoagulants Assessment in High Risk of Bleeding Patients with Non-Valvular Atrial Fibrillation.. <i>Geriatrics (Switzerland)</i> , 2022 , 7,	2.2	

8	A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 803233	5.4	
7	The Safety and Efficacy of Standard-Dose versus Low-Dose Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Left Atrial Appendage Thrombus.. <i>Journal of Healthcare Engineering</i> , 2021 , 2021, 1839399	3.7	○
6	Major gastrointestinal bleeding in patients receiving anticoagulant therapy for venous thromboembolism.. <i>Thrombosis Research</i> , 2022 , 214, 29-36	8.2	1
5	Concomitant Surgical Left Atrial Appendage Occlusion: a Review.. <i>Current Cardiology Reports</i> , 2022 ,	4.2	
4	Use of a mobile application for the control of anticoagulation with warfarin: a cluster randomized controlled clinical trial - Ijuí/RS/Brazil. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 58,	1.8	
3	Improving guideline-based anticoagulation in atrial fibrillation: A systematic literature review of prospective trials. 2022 ,		○
2	Oral Anticoagulation use in Non-valvular Atrial Fibrillation Patients in Rural Setting. 2022 , 100026		○
1	Family Physician Prescribing Practices and Perspectives on Shared Decision-Making Regarding the Use of Oral Anticoagulants for Stroke Prevention in Patients 75 Years or Older With Atrial Fibrillation. 2023 , 14, 215013192311640		○